Physician
Revived Soul Medical PC
Revived Soul Medical PC was paid $12.22M by Medicaid between Jan 2018 and Dec 2024, across 46 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 42% of everything it billed.
33Billing provider infoREVIVED SOUL MEDICAL PC
BROOKLYN, NY 11229
BROOKLYN, NY 11229
33aNPI1821389941assigned 04/23/2011
33bProvider typePsychiatry Physician
28Total paid$12.22M
24GClaims228,003
24DCodes billed46
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatry Physician providers in New York
Rank by total paid#3 of 1,033
Median peer was paid$8K
This provider vs. median1,581×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,085 | $1.67M | |
| 2019 | 46,244 | $1.46M | |
| 2020 | 24,431 | $1.38M | |
| 2021 | 28,700 | $1.90M | |
| 2022 | 24,759 | $1.97M | |
| 2023 | 23,357 | $2.00M | |
| 2024incomplete | 20,427 | $1.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 42% | 53,411 | 49,210 | $5.09M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 29% | 66,499 | 61,517 | $3.57M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 8.2% | 12,557 | 4,510 | $1.01M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.7% | 14,626 | 13,954 | $813K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.3% | 2,567 | 2,495 | $277K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 10,051 | 9,766 | $271K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 1.3% | 1,594 | 940 | $161K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 847 | 847 | $104K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 688 | 673 | $96K |
| 80342 | <1% | 3,039 | 2,982 | $67K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 692 | 668 | $62K |
| 80368 | <1% | 2,975 | 2,922 | $43K |
34 more codes
| 80371 | <1% | 2,952 | $42K | |
| 80357 | <1% | 2,987 | $41K | |
| 80360 | <1% | 2,876 | $39K | |
| 80338 | <1% | 1,622 | $36K | |
| 83992 | <1% | 3,711 | $35K | |
| 80333 | <1% | 1,600 | $34K | |
| 80355 | <1% | 2,190 | $30K | |
| 80372 | <1% | 1,856 | $27K | |
| 80361 | <1% | 3,541 | $27K | |
| 80346 | <1% | 3,784 | $27K | |
| 80356 | <1% | 3,427 | $25K | |
| 80336 | <1% | 1,787 | $25K | |
| 80365 | <1% | 3,444 | $25K | |
| 80366 | <1% | 1,708 | $24K | |
| 80359 | <1% | 3,751 | $23K | |
| 80354 | <1% | 1,524 | $23K | |
| 80373 | <1% | 1,496 | $23K | |
| 80363 | <1% | 1,863 | $23K | |
| 80324 | <1% | 3,596 | $23K | |
| 80369 | <1% | 1,424 | $22K | |
| 80353 | <1% | 3,442 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 84 | $15K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 124 | $14K |
| 80358 | <1% | 1,943 | $12K | |
| 80348 | <1% | 764 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 102 | $6K |
| 80362 | <1% | 591 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $918.65 |
| 80305 | <1% | 141 | $733.10 | |
| 93000 | <1% | 12 | $149.35 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 63 | $38.44 |
| 81002 | <1% | 14 | $21.79 | |
| 91300 | <1% | 13 | $0.02 | |
| 96127 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIBLITSKY, IRINA (OWNER)